Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitomycin C for Corneal Haze After CXL in Keratoconus
NCT04811924Phase 2Terminated
- Start
- Jul 2021
- Primary completion
- Feb 2023
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mitomycin c + TC-3 gel in keratoconus and corneal ectasia (2 arms). Primary endpoint: Corneal haze and scarring at 18 months. Started Jul 2021; status: terminated.
02
Drugs
mitomycin c + TC-3 gel
03
Conditions
keratoconuscorneal ectasia
Beyond the preview
Go deeper on NCT04811924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811924.